Molecular
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 167
- Market Cap
- $229.6M
- Introduction
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- MyeloidLeukemiaRelapsedAcute
- Interventions
- Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Molecular Partners AG
- Target Recruit Count
- 70
- Registration Number
- NCT05673057
- Locations
- 🇫🇷
IUCT Oncopole, Toulouse, France
🇫🇷AP-HP Hôpital Saint-Louis, Paris, France
🇫🇷CHU Bordeaux, Bordeaux, France
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
- Conditions
- Advanced Malignant Solid Tumor
- Interventions
- Drug: MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen)Drug: MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Molecular Partners AG
- Target Recruit Count
- 46
- Registration Number
- NCT05098405
- Locations
- 🇳🇱
NKI-AvL, Amsterdam, Netherlands
🇳🇱UMCU, Utrecht, Netherlands
🇫🇷Centre Léon Bérard, Lyon, Cedex 08, France
Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)
- Conditions
- COVID-19
- Interventions
- Drug: EnsovibepDrug: Placebo
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Molecular Partners AG
- Target Recruit Count
- 53
- Registration Number
- NCT04870164
- Locations
- 🇬🇧
HMR, London, United Kingdom
Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients
- Conditions
- Covid19
- Interventions
- Drug: ensovibep
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Molecular Partners AG
- Target Recruit Count
- 12
- Registration Number
- NCT04834856
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: MP0310
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Molecular Partners AG
- Target Recruit Count
- 38
- Registration Number
- NCT04049903
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Institut Claudius Regaud; Institut Universitaire du Cancer Toulouse Oncopole (IUCT-O), Toulouse, France
MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC
- Conditions
- EGFR-mutated NSCLC (Disorder)
- Interventions
- Combination Product: MP0250 DARPin® drug candidate, Osimertinib
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Molecular Partners AG
- Target Recruit Count
- 8
- Registration Number
- NCT03418532
- Locations
- 🇺🇸
Florida Hospital, Orlando, Florida, United States
🇺🇸University of California, San Diego, California, United States
🇺🇸Georgetown University, Washington, District of Columbia, United States
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma in Relapse
- Interventions
- Biological: MP0250 plus BOR+DEX
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Molecular Partners AG
- Target Recruit Count
- 33
- Registration Number
- NCT03136653
- Locations
- 🇦🇹
Hanusch Krankenhaus Wiener Gebietskrankenkasse, Wien, Vienna, Austria
🇦🇹Landeskliniken Salzburg Saint Johanns-Spital, Salzburg, Austria
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland
First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors
- Conditions
- Neoplasms
- Interventions
- Drug: MP0274
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- Molecular Partners AG
- Target Recruit Count
- 22
- Registration Number
- NCT03084926
- Locations
- 🇩🇪
Study Site Heidelberg, Heidelberg, Germany
🇩🇪Study Site Frankfurt, Frankfurt, Germany
🇬🇧Study Site Cambridge, Cambridge, United Kingdom
First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients
- Conditions
- Neoplasms
- Interventions
- Drug: MP0250
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Molecular Partners AG
- Target Recruit Count
- 58
- Registration Number
- NCT02194426
- Locations
- 🇨🇭
Study Site St. Gallen, St. Gallen, Saint Gallen, Switzerland
🇬🇧Study Site Oxford, Oxford, Oxfordshire, United Kingdom
🇬🇧Study Site Cambridge, Cambridge, Cambridgeshire, United Kingdom